NCT01748292View on ClinicalTrials.gov

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Macular Degeneration
Interventions
DRUG

0.5 mg ranibizumab

Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.

Trial Locations (4)

29169

Palmetto Retina Center, West Columbia

77030

Retina Consultants of Houston/The Medical Center, Houston

77384

Retina Consultants of Houston, The Woodlands

77494

Retina Consultants of Houston/Katy office, Katy

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Charles C Wykoff, PhD, MD

OTHER

NCT01748292 - Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab | Biotech Hunter | Biotech Hunter